Las quejas sobre deficiencias en Medicare Advantage son comunes, pero la supervisión federal es rara

Además de los dolores ocasionales, envejecer puede traer sorpresas desagradables y enfermedades graves. Las relaciones de largo plazo con doctores de confianza suelen hacer que incluso las malas noticias sean más llevaderas. Perder ese respaldo —especialmente en medio de una crisis de salud— puede ser aterrador. Por eso, existen requisitos federales poco conocidos que, se…

Read More

What real-world data will regulators consider in Europe?

A 2024 Data Quality Framework (DQF) from the European Medicines Agency (EMA) aims to provide some guidance for drug manufacturers. Here is a summary of that document. Factors to be considered when evaluating RWD Key factors to be considered in the EMA’s DQF include: Reliability: Are the data correct?Extensiveness: Are the data enoughCoherence: Are the…

Read More

When Drug Price Transparency Isn’t Enough

By KRISTINA SMITH & PHIYEN NGUYEN Policymakers and advocates often promote drug price transparency to lower costs and improve equity. While transparency is an important first step toward accountability and informed public budgeting, it does not guarantee affordable prices or fair access to medicines. Transparency Has Some Benefits Drug price transparency helps show how and…

Read More